JAGX
Price
$0.86
Change
-$0.02 (-2.27%)
Updated
Feb 21 closing price
Capitalization
11.2M
QLGN
Price
$3.55
Change
-$0.07 (-1.93%)
Updated
Feb 21 closing price
Capitalization
2.61M
Ad is loading...

JAGX vs QLGN

Header iconJAGX vs QLGN Comparison
Open Charts JAGX vs QLGNBanner chart's image
Jaguar Health
Price$0.86
Change-$0.02 (-2.27%)
Volume$116.52K
Capitalization11.2M
Qualigen Therapeutics
Price$3.55
Change-$0.07 (-1.93%)
Volume$11.56K
Capitalization2.61M
JAGX vs QLGN Comparison Chart
Loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JAGX vs. QLGN commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JAGX is a Hold and QLGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (JAGX: $0.86 vs. QLGN: $3.55)
Brand notoriety: JAGX and QLGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JAGX: 28% vs. QLGN: 18%
Market capitalization -- JAGX: $11.2M vs. QLGN: $2.61M
JAGX [@Biotechnology] is valued at $11.2M. QLGN’s [@Biotechnology] market capitalization is $2.61M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.51B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JAGX’s FA Score shows that 1 FA rating(s) are green whileQLGN’s FA Score has 1 green FA rating(s).

  • JAGX’s FA Score: 1 green, 4 red.
  • QLGN’s FA Score: 1 green, 4 red.
According to our system of comparison, both JAGX and QLGN are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JAGX’s TA Score shows that 3 TA indicator(s) are bullish while QLGN’s TA Score has 4 bullish TA indicator(s).

  • JAGX’s TA Score: 3 bullish, 5 bearish.
  • QLGN’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, QLGN is a better buy in the short-term than JAGX.

Price Growth

JAGX (@Biotechnology) experienced а -4.87% price change this week, while QLGN (@Biotechnology) price change was -2.80% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -1.71%. For the same industry, the average monthly price growth was -2.01%, and the average quarterly price growth was +0.86%.

Reported Earning Dates

JAGX is expected to report earnings on May 19, 2023.

QLGN is expected to report earnings on Mar 01, 2023.

Industries' Descriptions

@Biotechnology (-1.71% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAGX($11.2M) has a higher market cap than QLGN($2.61M). JAGX has higher P/E ratio than QLGN: JAGX (0.04) vs QLGN (0.00). JAGX (-15.238) and QLGN (-15.727) have similar YTD gains . QLGN has higher annual earnings (EBITDA): -6.73M vs. JAGX (-29.1M). JAGX has more cash in the bank: 13.3M vs. QLGN (388K). QLGN has less debt than JAGX: QLGN (1.43M) vs JAGX (34.3M). JAGX has higher revenues than QLGN: JAGX (10.5M) vs QLGN (0).
JAGXQLGNJAGX / QLGN
Capitalization11.2M2.61M429%
EBITDA-29.1M-6.73M432%
Gain YTD-15.238-15.72797%
P/E Ratio0.040.004,221%
Revenue10.5M0-
Total Cash13.3M388K3,428%
Total Debt34.3M1.43M2,392%
FUNDAMENTALS RATINGS
JAGX vs QLGN: Fundamental Ratings
JAGX
QLGN
OUTLOOK RATING
1..100
91
VALUATION
overvalued / fair valued / undervalued
1..100
18
Undervalued
31
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6593
P/E GROWTH RATING
1..100
10051
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (18) in the Pharmaceuticals Generic industry is in the same range as QLGN (31) in the null industry. This means that JAGX’s stock grew similarly to QLGN’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as QLGN (100) in the null industry. This means that JAGX’s stock grew similarly to QLGN’s over the last 12 months.

JAGX's SMR Rating (100) in the Pharmaceuticals Generic industry is in the same range as QLGN (100) in the null industry. This means that JAGX’s stock grew similarly to QLGN’s over the last 12 months.

JAGX's Price Growth Rating (65) in the Pharmaceuticals Generic industry is in the same range as QLGN (93) in the null industry. This means that JAGX’s stock grew similarly to QLGN’s over the last 12 months.

QLGN's P/E Growth Rating (51) in the null industry is somewhat better than the same rating for JAGX (100) in the Pharmaceuticals Generic industry. This means that QLGN’s stock grew somewhat faster than JAGX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
JAGXQLGN
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
87%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Momentum
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
71%
MACD
ODDS (%)
Bullish Trend 3 days ago
71%
Bullish Trend 3 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
80%
Bullish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
82%
Bearish Trend 3 days ago
90%
Advances
ODDS (%)
Bullish Trend 5 days ago
84%
Bullish Trend 10 days ago
81%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
N/A
Bearish Trend 3 days ago
90%
View a ticker or compare two or three
Ad is loading...
JAGX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
QLGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
RPM121.19-1.96
-1.59%
RPM International
EMBC14.10-0.31
-2.15%
Embecta Corp
MEOH44.25-1.44
-3.15%
Methanex Corp
OLB1.26-0.04
-3.45%
OLB Group Inc. (The)
DSP21.01-1.27
-5.70%
Viant Technology

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
-2.86%
HEPA - JAGX
29%
Poorly correlated
-9.20%
VXRT - JAGX
28%
Poorly correlated
+1.21%
DVHGF - JAGX
27%
Poorly correlated
+54.55%
AFMD - JAGX
26%
Poorly correlated
+1.96%
SNPX - JAGX
26%
Poorly correlated
+1.06%
More

QLGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, QLGN has been loosely correlated with VERU. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if QLGN jumps, then VERU could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To QLGN
1D Price
Change %
QLGN100%
-1.99%
VERU - QLGN
34%
Loosely correlated
-2.88%
PHIO - QLGN
32%
Poorly correlated
-2.91%
ZLDAF - QLGN
29%
Poorly correlated
N/A
MNOV - QLGN
28%
Poorly correlated
+3.10%
JAGX - QLGN
28%
Poorly correlated
-2.86%
More